Abstract: The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.

Abstract: A transformable Unmanned Aerial Vehicle (UAV), can operate as a coplanar hexacopter or as an omnidirectional multirotor based on different operation modes. The UAV has 100% force efficiency for launching or landing tasks in the coplanar mode. In the omnidirectional mode, the UAV is fully actuated in the air for agile mobility in six degrees of freedom (DOFs). Models and control design are developed to characterize the motion of the transformable UAV. Simulation results are presented to validate the transformable UAV design and the enhanced UAV performance, compared with a fixed structure.

Abstract: The present disclosure relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof and (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof. The present disclosure also relates to a pharmaceutical combination comprising (1) a first agent which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, (2) a second agent which is an anti-hormonal agent or a pharmaceutically acceptable salt thereof, and (3) a third agent which is an agent that regulates the PI3K/Akt/mTOR pathway or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are embodiments of a pyrazole compound according to formula I. Compositions comprising the compound, and a method for making the composition also are disclosed. The composition may comprise a carrier, such as a polymer and/or the composition may be a spray-dried formulation. Also disclosed is a method for using the compound and/or composition. The compound and/or composition may be useful to inhibit an IRAK protein and/or to ameliorate, treat and/or prevent an IRAK-associated disease or condition in a subject.

Abstract: Embodiments of this application provide a power headroom reporting method for user equipment, a medium, and user equipment. The reporting method includes: The user equipment has at least a first uplink transmit antenna and a second uplink transmit antenna, the first uplink transmit antenna has a first P_MPR value, and the second uplink transmit antenna has a second P_MPR value; and when the user equipment performs uplink data transmission in a single-stream manner, the user equipment sends a first PHR value to a network side, where the first PHR value is obtained based on at least a third power management maximum power reduction P_MPR value, and the third power management maximum power reduction P_MPR value is between the first P_MPR value and the second P_MPR value.

Abstract: Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitor compounds and compositions comprising such compounds. The compounds may have a structure according to Formula I Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

Abstract: A novel synthetic crystalline borongermanosilicate molecular sieve material, designated boron SSZ-117x, is provided. The boron SSZ-117x can be synthesized using N,N,N,3,5-pentamethyladamantan-1-ammonium cations as a structure directing agent. The synthesis employs a boron pathway to achieve the boron molecular sieve. The boron SSZ-117x may be used in organic compound conversion reactions, such as reforming, and/or sorptive processes.

Abstract: A focus ring for a plasma-based semiconductor processing tool is designed to provide and/or ensure etch rate uniformity across a wafer during a plasma etch process. The focus ring may include an angled inner wall that is angled away from a center of the focus ring to direct a plasma toward the wafer. The angle of the angled inner wall may be greater than approximately 130 degrees relative to the top surface of the wafer and/or may be less than approximately 50 degrees relative to an adjacent lower surface of the focus ring to reduce and/or eliminate areas of overlapping plasma on the wafer (which would otherwise cause non-uniform etch rates). Moreover, an inner diameter may be configured to be in a range of approximately 209 millimeters to 214 millimeters to further reduce and/or eliminate areas of overlapping plasma on the wafer.

Abstract: Provided is a novel synthetic crystalline borongermanosilicate molecular sieve material, designated boron SSZ-113. The boron SSZ-113 can be synthesized using 1,3 bis(2,3-dimethyl-1H-imidazolium) propane dications as a structure directing agent. The boron SSZ-113 may be used in organic compound conversion reactions and/or sorptive processes, and in particular, in reforming reactions.

Abstract: A novel synthetic crystalline molecular sieve material, designated boron SSZ-121 is provided. The boron SSZ-121 can be synthesized using 1,3-bis(1-adamantyl)imidazolium cations as a structure directing agent. The boron SSZ-121 may be used in organic compound conversion reactions and/or sorptive processes.

Abstract: Provided are CD19 binding molecules, including anti-CD19 antibodies, including antibody fragments such as single-chain fragments, and chimeric receptors including the antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, including those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies display similar functional properties to the reference antibodies, such as comparable binding affinities and/or competitive inhibition properties. Also provided are genetically engineered cells expressing the chimeric receptors, and uses of the binding molecules and cells adoptive cell therapy.

Abstract: The present invention is a grinder head for attaching to a track cleaner. The present invention also includes the grinder head attached to a track cleaner. Preferably, the present invention will continuously grind and load hard frozen minerals like taconite or ice. In addition, the present invention preferably aids in removal of hard-to-handle material such as wet, sticky bentonite from tracks which can be difficult in the summer months. The grinder head attachment will preferably allow operators to use a track cleaner to remove materials, preferably in one pass, during the colder months when the bentonite is frozen and much easier to handle. Preferably, the present invention will also be able to remove concrete or asphalt surfaces at road crossings.

Abstract: An implantable device is configured to be positioned within a native heart valve to allow the native heart valve to form a more effective seal. The implantable device includes a cover. The cover can be attached to one or more sleeves, can have a portion that has a lower coefficient of friction, and/or can have separate pieces that cover different portions of the implantable device.

Abstract: Disclosed herein are methods and compositions for corresponding positions on an array with differently labeled affinity reagents immobilized at the positions. A first and a second affinity reagents are immobilized on at least some of the first and second positions, respectively. The first affinity reagent and the second affinity reagent are associated with a first luciferase polypeptide and a second luciferase polypeptide, respectively. The first luciferase polypeptide does not cross react with the second substrate and the second luciferase polypeptide does not cross react with the first substrate. The method further comprises contacting the array with the first substrate, which reacts with the first luciferase polypeptide and detecting the first luminescent signal and detecting the second luminescent signal at positions, thereby corresponding positions on an array with the first affinity reagent or the second affinity reagent immobilized at the positions.

Abstract: Provided herein are BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and chimeric receptors comprising the anti-BCMA binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-BCMA antibodies or antigen-binding fragments thereof specifically bind to BCMA-1. Among the anti-BCMA antibodies are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs or BCMA-binding molecules and uses thereof such as in adoptive cell therapy.

Abstract: The disclosure discloses a large-aperture infrared metalens camera, which belongs to the technical field of infrared imaging and micro-nano photonics, including a large-aperture metalens, an infrared focal plane array detector, a metalens mechanical assembly and a housing. The large-aperture metalens has an aperture greater than 50 mm and a thickness less than 2 mm, and the distance between the large-aperture metalens and the infrared focal plane array detector is greater than 30 mm. The disclosure adopts strict electromagnetic field values, diffraction design algorithm and large-area semiconductor process manufacturing method to increase the aperture of metalens to 50 mm or more, and considerably improves the focal length and magnification of the camera while ensuring that the F-number of the metalens meets the requirements of signal-to-noise ratio of image. The problems of short focal length, small magnification, and insufficient imaging range of conventional metalens cameras are overcome.

Abstract: Methods for designing orthodontic appliances for repositioning a patient's teeth are provided. In some embodiments, a method includes determining a movement path to move one or more teeth from an initial arrangement to a target arrangement, determining a force system to produce movement of the one or more teeth along the movement path, and determining an appliance geometry for an orthodontic appliance configured to produce the force system. The orthodontic appliance can include an outer shell comprising a plurality of teeth-receiving cavities and an inner structure positioned on an inner surface of the outer shell. The inner structure can have an elastic modulus different than an elastic modulus of the outer shell. The method can also include generating instructions for directly fabricating the orthodontic appliance using a layer-by-layer additive manufacturing technique.

Abstract: The present invention provides antigen-binding polypeptides, including bi-specific antigen-binding polypeptides, that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to HER2 and antagonize HER2 activation. The invention also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen binding polypeptides. Methods of using antigen-binding polypeptide of the invention to treat disease, including cancer, are also encompassed by the invention.

Abstract: Embodiments of this application provide a data transmission method, a network device, and a terminal device. The method may include detecting, by a network device, a first signal in an uplink signal. The method may also include determining, by the network device, a signal structure of the uplink signal based on a result of detecting the first signal. Furthermore, the method may include receiving, by the network device, the uplink signal based on the signal structure, and/or responding to the uplink signal based on the signal structure. According to the data transmission method in the embodiments of this application, before receiving data, the network device can determine the signal structure, used by the terminal device, of the uplink signal, and then use a corresponding receiving method to avoid complexity and a reliability risk that are caused by completely blind detection performed by the network device.

Abstract: A processing device in a memory system connects a first data block of the memory device to a second data block of the memory device to generate a combined data block comprising a first plurality of sub-blocks of the first data block and a second plurality of sub-blocks of the second data block, wherein the connecting includes: for each wordline of a first plurality of wordlines of the first data block, creating a wordline connection short between the respective wordline of the first data block and a corresponding wordline of a second plurality of wordlines of the second data block, wherein the first plurality of wordlines and the second plurality of wordlines comprise data wordlines; and driving a first data wordline of the first data block and a second wordline of the second data block using a single string driver of the memory device.